Skip to main content

Aligos Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

ALGS$3.95-2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

ExhibitNumber · Exhibit Description · Incorporated by Reference · ProvidedHerewith
Form · Date · Number
3.1 (a)Amended and Restated Certificate of Incorporation.8-K10/20/20203.1
3.1 (b)Certificate of Amendment to Amended and Restated Certificate of Incorporation.8-K6/28/20243.1
3.2Amended and Restated Bylaws.8-K10/20/20203.2
4.1Reference is made to Exhibits 3.1(a), 3.1(b) and 3.2.
4.2Form of Common Stock Certificate.S-1/A10/9/20204.2
4.3Form of Common Warrant Agreement.8-K10/25/20234.2
4.4Form of Pre-Funded Warrant Agreement.8-K10/25/20234.1
10.1#Non-Employee Director Compensation Policy.X
10.2#Amendment to the Aligos Therapeutics, Inc. 2020 Incentive Award Plan.8-K6/28/202410.1
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
32.1*Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
32.2*Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
101.INSInline XBRL Instance Document.X
101.SCHInline XBRL Taxonomy Extension Schema Document.X
104The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 has been formatted in Inline XBRL.X
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.